A sequential double blind cross-over trial of tocainide hydrochloride in tinnitus.
A sequential double blind cross-over trial of tocainide hydrochloride, an oral analogue of lignocaine, is reported. The dosage of tocainide hydrochloride ranged from 200-600 mg daily. Of the 32 patients who completed the trial, 1 had complete relief and 2 had partial relief of their tinnitus whilst taking tocainide. An increased incidence of side-effects in patients taking tocainide was noted, in particular, headache, dizziness, nausea and skin rashes.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D014012:Tinnitus / Q000188:drug therapy*; D016677:Tocainide
D016677:Tocainide; D008012:Lidocaine